Ga-FAPI-46 PET/CT
Phase 2Small molecule
Ga-FAPI-46 PET/CT is one of 9 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Head and Neck Carcinoma
#DrugCompanyPhaseTrials
1IC-Green
PProvepharm SAS
Approved
Erbitux
IImclone
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Keytruda
Merck & Co.Phase 2
VESANOID
UUniversity of Colorado, Denver
Phase 3
Ga-FAPI-46 PET/CT
JJohn O. Prior
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-FAPI-46 PET/CT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJohn O. Prior